View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCowen 将来の成長Future 基準チェック /06主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長11.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジLow最終更新日20 Feb 2023今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 10Cowen Inc. to Report Q4, 2022 Results on Feb 17, 2023Cowen Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 17, 2023お知らせ • Jan 13Cowen Inc. Announces the Demise of Jack H. Nusbaum, DirectorCowen Inc. announced with great sadness that Director Jack H. Nusbaum passed away unexpectedly on January 11, 2021. Mr. Nusbaum has served as a member of Cowen’s Board since November 2009. He has been an advisor and friend to members of the Company’s leadership for over 30 years. Mr. Nusbaum was also a Senior Partner of the New York law firm of Willkie Farr & Gallagher LLP, serving as the firm’s Chairman from 1987 through 2009 and a partner in that firm for fifty years.お知らせ • Jan 06Joram Siegel Joins Cowen as Head of Fixed Income Outsourced TradingCowen Inc. announced that Joram Siegel has joined its Outsourced Trading division as Managing Director, Head of Fixed Income Outsourced Trading. Mr. Siegel will be based in New York and report to Michael Rosen and Jack Seibald, Global Co-Heads of Prime Brokerage and Outsourced Trading. Mr. Siegel brings more than 20 years of practice in credit markets to Cowen. Prior to joining Cowen, Mr. Siegel spent six years at Mitsubishi UFJ Financial Group in New York and London, where he most recently served as Managing Director, Head of Credit Americas and Global Credit Coordinator.お知らせ • Oct 01Cowen Grows Special Situations Group with Addition of Kenneth Garnett as Managing DirectorCowen Inc. announced that Kenneth Garnett has joined the firm’s Investment Banking team as a Managing Director in the Special Situations Group. Mr. Garnett will be based in New York and report to Lorie Beers, Cowen Managing Director and Head, Special Situations & Restructuring. He brings over two decades of experience in special situation private investing, restructuring investment banking and turnaround consulting. Mr. Garnett has spent over 20 years working in private equity investing, restructuring, investment banking and turnaround consulting. For the past six years, Mr. Garnett worked at Conway MacKenzie as Managing Director, Private Fund Services. Previously, he was a Partner and Founder at Renewal Capital, a private equity fund making special situations investments in the lower middle market, as well as a partner at investment bank Gordian Group.お知らせ • Sep 25+ 1 more updateClinical Data, Inc. (NasdaqNM:CLDA) entered into an agreement to acquire Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) for $56.9 million.Clinical Data, Inc. (NasdaqNM:CLDA) entered into an agreement to acquire Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) for $56.9 million on June 20, 2005. Under the terms of the agreement, each shareholder of 35.35 million outstanding Genaissance Pharmaceuticals, Inc.'s common stock will receive 0.065 shares of Clinical Data, Inc.'s common stock, each shareholder of 0.46 million outstanding Genaissance Pharmaceuticals, Inc.'s Series A preferred stock will receive 1.052326 shares of newly designated Clinical Data, Inc.'s Series A preferred stock, and Clinical Data, Inc. will also assume all existing Genaissance Pharmaceuticals, Inc.'s options. Xmark Asset Management, LLC agreed to sell its stake in the transaction. In the event of termination, Genaissance is required to pay Clinical Data a termination fee of $1.33 million. Upon completion of the acquisition, Kevin Rakin and Joseph Klein III of Genaissance Pharmaceuticals, Inc. will join Clinical Data, Inc.'s Board of Directors. The transaction is subject to shareholders' approval and has been unanimously approved by the Board. The transaction is expected to close by fourth quarter. WR Hambrecht + Co., LLC acted as financial advisor and John Hession, Marc Recht, Dr. Simona Levi-Minzi, Angelo Mignanelli, Revecca Schuster, Luke Albrecht, Jeff Wagner, Chip Kerby, Mark Collins, and Daphne Van de Meerssche of McDermott Will & Emery LLP acted as legal advisor to Clinical Data, Inc. CIBC World Markets Corp. acted as financial advisor and Steven D. Singer of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor to Genaissance Pharmaceuticals Inc. Michael A. Gordon of Sidley Austin Brown & Wood LLP acted as legal advisor to Ritchie Capital Management, LLC. Oppenheimer & Co. Inc. acted as financial advisor to Genaissance Pharmaceuticals, Inc.お知らせ • Sep 16Merck & Co. Inc. (NYSE: MRK) entered into a definitive agreement to acquire Sirna Therapeutics Inc. (NasdaqNM: RNAI) from New Leaf Venture Partners, LLC, GGV Capital, TVM Capital Life Science Venture Capital and others for a consideration approximately $1.1 billion in cash.Merck & Co. Inc. (NYSE: MRK) entered into a definitive agreement to acquire Sirna Therapeutics Inc. (NasdaqNM: RNAI) from New Leaf Venture Partners, LLC, GGV Capital, TVM Capital Life Science Venture Capital and others for approximately $1.1 billion in cash, on October 30, 2006. Under the terms of the agreement, Merck & Co. Inc. will pay $13 for each share of Sirna Therapeutics, for a total consideration of approximately $948.5 million in cash. Also, Merck & Co. Inc. will pay a consideration of approximately $57.6 million in cash, for all the outstanding options of Sirna Therapeutics as on June 30, 2006. Each option is valued at $10 with an exercise price of $3. Merck & Co. Inc. will pay a consideration of $127.30 million in cash, for all the outstanding warrants of Sirna Therapeutics as on December 31, 2005. Each warrant is valued at $10.93 with an exercise price of $2.07. If the agreement is cancelled, then Sirna Therapeutics will pay Merck & Co., Inc., a termination fee of $42.1 million. The acquisition is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, approval by the stockholders of Sirna, resignations of the board of directors of Sirna, approval by governmental entities, consents of all third parties and other customary closing conditions. Sirna stockholders owning approximately 36% of Sirna's outstanding shares have committed to support the transaction and have entered into voting agreements. The board of directors of both Merck & Co. and Sirna has unanimously approved the agreement. The two companies expect to complete the acquisition in the first quarter of 2007. The termination fee was amended to $38 million. Goldman, Sachs & Co. was the financial advisor and Michael J. Kennedy and Sam Zucker from O’Melveny & Myers LLP were the legal advisors for Sirna Therapeutics Inc. David N. Shine and Brian T. Mangino from Fried, Frank, Harris, Shriver & Jacobson LLP were the legal advisors for Merck & Co., Inc. on the deal. Morgan Stanley was financial advisor for Merck. Latham & Watkins LLP was the legal advisor to Goldman, Sachs & Co. Morris, Nichols, Arsht & Tunnell LLP was legal advisor for Merck & Co. The Altman Group acted as information agent to Sirna and received $10,000 as fees. Sirna agreed to pay Goldman Sachs & Co. LLC an advisory fees of approximately $13.47 million of which $3.37 million payable upon announcement of the merger and $10.1 million payable on consummation of the merger.業績と収益の成長予測OTCPK:CWGR.P - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20231,439111N/AN/A212/31/20221,27970N/AN/AN/A9/30/20221,394122-106-91N/A6/30/20221,42814588100N/A3/31/20221,576176-379-366N/A12/31/20211,901289295307N/A9/30/20211,985316688695N/A6/30/20211,899298544554N/A3/31/20212,100367946955N/A12/31/20201,566210502513N/A9/30/20201,272123249267N/A6/30/20201,183106165183N/A3/31/2020838-2-145-129N/A12/31/201999018-202-187N/A9/30/201986918-138-128N/A6/30/2019868295869N/A3/31/201982529221230N/A12/31/201885536316324N/A9/30/2018803-45166176N/A6/30/2018772-56-104-99N/A3/31/2018710-541421N/A12/31/2017585-68-33N/A9/30/20175186104108N/A6/30/2017460-1132135N/A3/31/2017420-19-71-67N/A12/31/2016410-26-367-352N/A9/30/20163926N/A-228N/A6/30/2016390-1N/A-265N/A3/31/201639318N/A-367N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CWGR.Pの予測収益成長が 貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CWGR.Pの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CWGR.Pの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CWGR.Pの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: CWGR.Pの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CWGR.Pの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/03/02 00:44終値2022/12/30 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cowen Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Guy MoszkowskiBofA Global ResearchDevin RyanCitizens JMP Securities, LLCJames YaroGoldman Sachs5 その他のアナリストを表示
お知らせ • Feb 10Cowen Inc. to Report Q4, 2022 Results on Feb 17, 2023Cowen Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 17, 2023
お知らせ • Jan 13Cowen Inc. Announces the Demise of Jack H. Nusbaum, DirectorCowen Inc. announced with great sadness that Director Jack H. Nusbaum passed away unexpectedly on January 11, 2021. Mr. Nusbaum has served as a member of Cowen’s Board since November 2009. He has been an advisor and friend to members of the Company’s leadership for over 30 years. Mr. Nusbaum was also a Senior Partner of the New York law firm of Willkie Farr & Gallagher LLP, serving as the firm’s Chairman from 1987 through 2009 and a partner in that firm for fifty years.
お知らせ • Jan 06Joram Siegel Joins Cowen as Head of Fixed Income Outsourced TradingCowen Inc. announced that Joram Siegel has joined its Outsourced Trading division as Managing Director, Head of Fixed Income Outsourced Trading. Mr. Siegel will be based in New York and report to Michael Rosen and Jack Seibald, Global Co-Heads of Prime Brokerage and Outsourced Trading. Mr. Siegel brings more than 20 years of practice in credit markets to Cowen. Prior to joining Cowen, Mr. Siegel spent six years at Mitsubishi UFJ Financial Group in New York and London, where he most recently served as Managing Director, Head of Credit Americas and Global Credit Coordinator.
お知らせ • Oct 01Cowen Grows Special Situations Group with Addition of Kenneth Garnett as Managing DirectorCowen Inc. announced that Kenneth Garnett has joined the firm’s Investment Banking team as a Managing Director in the Special Situations Group. Mr. Garnett will be based in New York and report to Lorie Beers, Cowen Managing Director and Head, Special Situations & Restructuring. He brings over two decades of experience in special situation private investing, restructuring investment banking and turnaround consulting. Mr. Garnett has spent over 20 years working in private equity investing, restructuring, investment banking and turnaround consulting. For the past six years, Mr. Garnett worked at Conway MacKenzie as Managing Director, Private Fund Services. Previously, he was a Partner and Founder at Renewal Capital, a private equity fund making special situations investments in the lower middle market, as well as a partner at investment bank Gordian Group.
お知らせ • Sep 25+ 1 more updateClinical Data, Inc. (NasdaqNM:CLDA) entered into an agreement to acquire Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) for $56.9 million.Clinical Data, Inc. (NasdaqNM:CLDA) entered into an agreement to acquire Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) for $56.9 million on June 20, 2005. Under the terms of the agreement, each shareholder of 35.35 million outstanding Genaissance Pharmaceuticals, Inc.'s common stock will receive 0.065 shares of Clinical Data, Inc.'s common stock, each shareholder of 0.46 million outstanding Genaissance Pharmaceuticals, Inc.'s Series A preferred stock will receive 1.052326 shares of newly designated Clinical Data, Inc.'s Series A preferred stock, and Clinical Data, Inc. will also assume all existing Genaissance Pharmaceuticals, Inc.'s options. Xmark Asset Management, LLC agreed to sell its stake in the transaction. In the event of termination, Genaissance is required to pay Clinical Data a termination fee of $1.33 million. Upon completion of the acquisition, Kevin Rakin and Joseph Klein III of Genaissance Pharmaceuticals, Inc. will join Clinical Data, Inc.'s Board of Directors. The transaction is subject to shareholders' approval and has been unanimously approved by the Board. The transaction is expected to close by fourth quarter. WR Hambrecht + Co., LLC acted as financial advisor and John Hession, Marc Recht, Dr. Simona Levi-Minzi, Angelo Mignanelli, Revecca Schuster, Luke Albrecht, Jeff Wagner, Chip Kerby, Mark Collins, and Daphne Van de Meerssche of McDermott Will & Emery LLP acted as legal advisor to Clinical Data, Inc. CIBC World Markets Corp. acted as financial advisor and Steven D. Singer of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor to Genaissance Pharmaceuticals Inc. Michael A. Gordon of Sidley Austin Brown & Wood LLP acted as legal advisor to Ritchie Capital Management, LLC. Oppenheimer & Co. Inc. acted as financial advisor to Genaissance Pharmaceuticals, Inc.
お知らせ • Sep 16Merck & Co. Inc. (NYSE: MRK) entered into a definitive agreement to acquire Sirna Therapeutics Inc. (NasdaqNM: RNAI) from New Leaf Venture Partners, LLC, GGV Capital, TVM Capital Life Science Venture Capital and others for a consideration approximately $1.1 billion in cash.Merck & Co. Inc. (NYSE: MRK) entered into a definitive agreement to acquire Sirna Therapeutics Inc. (NasdaqNM: RNAI) from New Leaf Venture Partners, LLC, GGV Capital, TVM Capital Life Science Venture Capital and others for approximately $1.1 billion in cash, on October 30, 2006. Under the terms of the agreement, Merck & Co. Inc. will pay $13 for each share of Sirna Therapeutics, for a total consideration of approximately $948.5 million in cash. Also, Merck & Co. Inc. will pay a consideration of approximately $57.6 million in cash, for all the outstanding options of Sirna Therapeutics as on June 30, 2006. Each option is valued at $10 with an exercise price of $3. Merck & Co. Inc. will pay a consideration of $127.30 million in cash, for all the outstanding warrants of Sirna Therapeutics as on December 31, 2005. Each warrant is valued at $10.93 with an exercise price of $2.07. If the agreement is cancelled, then Sirna Therapeutics will pay Merck & Co., Inc., a termination fee of $42.1 million. The acquisition is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, approval by the stockholders of Sirna, resignations of the board of directors of Sirna, approval by governmental entities, consents of all third parties and other customary closing conditions. Sirna stockholders owning approximately 36% of Sirna's outstanding shares have committed to support the transaction and have entered into voting agreements. The board of directors of both Merck & Co. and Sirna has unanimously approved the agreement. The two companies expect to complete the acquisition in the first quarter of 2007. The termination fee was amended to $38 million. Goldman, Sachs & Co. was the financial advisor and Michael J. Kennedy and Sam Zucker from O’Melveny & Myers LLP were the legal advisors for Sirna Therapeutics Inc. David N. Shine and Brian T. Mangino from Fried, Frank, Harris, Shriver & Jacobson LLP were the legal advisors for Merck & Co., Inc. on the deal. Morgan Stanley was financial advisor for Merck. Latham & Watkins LLP was the legal advisor to Goldman, Sachs & Co. Morris, Nichols, Arsht & Tunnell LLP was legal advisor for Merck & Co. The Altman Group acted as information agent to Sirna and received $10,000 as fees. Sirna agreed to pay Goldman Sachs & Co. LLC an advisory fees of approximately $13.47 million of which $3.37 million payable upon announcement of the merger and $10.1 million payable on consummation of the merger.